Carolyn Tang Sells 6,810 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) General Counsel Carolyn Tang sold 6,810 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total value of $150,909.60. Following the transaction, the general counsel directly owned 124,734 shares in the company, valued at $2,764,105.44. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $21.99 on Friday. The stock has a market cap of $2.37 billion, a P/E ratio of -6.39 and a beta of 0.75. The firm’s fifty day simple moving average is $21.10 and its 200 day simple moving average is $14.13. Arcus Biosciences, Inc. has a twelve month low of $6.50 and a twelve month high of $26.40. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.06. The business had revenue of $26.00 million during the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company’s revenue for the quarter was down 45.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.00) EPS. As a group, research analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. The Goldman Sachs Group increased their target price on Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research report on Monday. HC Wainwright boosted their target price on shares of Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Friday, December 12th. Truist Financial set a $30.00 price target on shares of Arcus Biosciences in a research note on Friday, December 12th. Finally, Wells Fargo & Company lifted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, October 20th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and an average price target of $28.89.

More Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high‑visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy‑side attention ahead of catalysts. Arcus to Present at JPM
• Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
• Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short‑term selling pressure. See CEO SEC filing for details. CEO Form 4
• Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Hedge Funds Weigh In On Arcus Biosciences

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after purchasing an additional 1,298,584 shares in the last quarter. Woodline Partners LP raised its holdings in Arcus Biosciences by 45.5% in the first quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after buying an additional 1,603,367 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Arcus Biosciences by 14.9% in the second quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock worth $12,995,000 after buying an additional 207,097 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Arcus Biosciences by 173.5% in the third quarter. Bank of America Corp DE now owns 1,360,781 shares of the company’s stock worth $18,507,000 after buying an additional 863,162 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Arcus Biosciences by 35.3% during the third quarter. Wellington Management Group LLP now owns 1,266,289 shares of the company’s stock valued at $17,222,000 after buying an additional 330,268 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.